Pramlintide

Label FDA-approved

ClassAmylin receptor agonist

Typical routes in papersSC with meals on label

Half-life context~48 minutes

EvidenceFDA-approved (Symlin)

What it is

Pramlintide is injectable amylin for insulin-using diabetes (Symlin). It slows the stomach, lowers post-meal glucagon, and adds fullness.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

On the label it helps blunt after-meal sugar spikes and can add a little weight loss.
It is the ancestor idea behind newer long-acting amylins like cagrilintide.
Mealtime shots plus insulin means hypoglycemia risk if insulin is not reduced per label.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Amylin receptor agonism: decelerated gastric emptying, suppressed glucagon, central satiety.

Possible side effects / caveats

Nausea, hypoglycemia with insulin, boxed warning language on the insert. Research vials are not Symlin pens.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Label (type 1, example)	15 mcg titrated toward 30–60 mcg	Before major meals	Confirm current insert
Label (type 2, example)	60 mcg titrated toward 120 mcg	Before major meals	Confirm current insert

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.